Estimated Reduction in Cardiovascular Risk Associated With Hypoxic Burden Improvement With AD109 in the LunAIRo and SynAIRgy Phase 3 Studies for Obstructive Sleep Apnea

aroxybutynin/atomoxetine (AD109) - Apnimed

Reena Mehra, MD, MSCR, ATSF; Luigi Taranto-Montemurro, MD; Ali Azarbarzin, PhD; Patrick J. Strollo, MD, ATSF; Laura K. Gell, PhD; Huy Pho, BS

Mar 3, 2026